Christina L Fanola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/131872/publications.pdf

Version: 2024-02-01

1478505 1720034 8 445 6 7 citations h-index g-index papers 9 9 9 1040 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine, 2018, 379, 1107-1117.	27.0	205
2	EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF $\hat{a} \in \text{``IIMI 48 RANDOMIZED CLINICAL TRIAL.}$ Journal of the American College of Cardiology, 2017, 69, 325.	2.8	159
3	A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. European Heart Journal, 2017, 38, ehw565.	2.2	37
4	Incidence of severe renal dysfunction among individuals taking warfarin and implications for non–vitamin K oral anticoagulants. American Heart Journal, 2017, 184, 150-155.	2.7	18
5	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. American Heart Journal, 2018, 202, 39-48.	2.7	15
6	Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran. Vascular Health and Risk Management, 2015, 11, 271.	2.3	7
7	TIMIâ€AF score and cardiovascular events in vitamin K antagonistsâ€naà ve outpatients with atrial fibrillation. Clinical Cardiology, 2018, 41, 1252-1258.	1.8	4
8	BLOOD PRESSURE, SUBCLINICAL MYOCARDIAL INJURY AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH DIABETES AND HIGH CARDIOVASCULAR RISK: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL. Journal of the American College of Cardiology, 2017, 69, 1653.	2.8	0